TRBV30: A Promising Drug Target for Cancer and Other Diseases

Target Name: TRBV30

NCBI ID: G28557

TRBV30

Other Name(s): TCRBV20S1A1N2 | T cell receptor beta variable 30 | TCRBV30S1

TRBV30: A Promising Drug Target for Cancer and Other Diseases

TRBV30 (TcRBV20S1A1N2) is a drug target (or biomarker) that has been identified and targeted for drug development due to its unique structure and bioavailability. TRBV30 is a small non-coding RNA molecule that is expressed in various tissues and cells, including the brain, heart, and liver. It has been shown to play a critical role in the development and progression of various diseases, including cancer.

One of the key reasons why TRBV30 has been identified as a potential drug target is its unique structure. TRBV30 is a double-stranded RNA molecule that consists of two domains: an N-domain and a C-domain. The N-domain is responsible for binding to DNA and RNA, while the C-domain is responsible for the formation of a double-stranded RNA molecule. This unique structure allows TRBV30 to interact with other molecules and to have a significant impact on various biological processes.

Another reason why TRBV30 has been targeted for drug development is its bioavailability. TRBV30 is expressed in various tissues and cells, including the brain, heart, and liver, which makes it an attractive target for drug development due to its potential to affect a wide range of cells and tissues. Additionally, TRBV30 is a relatively stable molecule, which has been shown to be resistant to various treatments and conditions.

In addition to its unique structure and bioavailability, TRBV30 has also been shown to play a critical role in the development and progression of various diseases. Studies have shown that high levels of TRBV30 are associated with the development of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Additionally, TRBV30 has been shown to play a critical role in the regulation of various biological processes, including cell growth, apoptosis, and inflammation.

Due to its unique structure, bioavailability, and role in the development and progression of various diseases, TRBV30 has been identified as a promising drug target for drug development. Further research is being conducted to determine the exact mechanisms by which TRBV30 functions and to identify potential drugs that can target it. This research has the potential to lead to the development of new treatments for a wide range of diseases.

Protein Name: T Cell Receptor Beta Variable 30

Functions: V region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRBV30 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBV30 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets